A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

Trial Profile

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs A002-MeiraGTx (Primary)
  • Indications Colour vision defects
  • Focus Adverse reactions
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 07 Nov 2017 According to an Applied Genetic Technologies Corporation media release, the company has found evidence of biological activity at lower vector doses than those originally proposed for the ACHM B3 (NCT02599922) study and has elected to adjust the dose downward in this dose ranging study. This new dose will also apply to the ACHM A3 study.
    • 13 Sep 2017 According to Applied Genetic Technologies Corporation media release, the company is currently conducting site initiation activities and screening patients for enrollment in this Phase 1/2.
    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top